A Phase I, Double-blind, Randomized, Sham-controlled, Dose-response, Study Evaluating the Safety and Tolerability of TG-C in Subjects With Chronic Discogenic Lumbar Back Pain Due to Degenerative Disc Disease at 6 and 12 Months

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tonogenchoncel-L (Primary)
Indications Intervertebral disc degeneration
Focus Adverse reactions
Sponsors Kolon TissueGene

Most Recent Events

26 Jan 2024 Planned End Date changed from 1 Nov 2026 to 1 Nov 2027.
26 Jan 2024 Planned primary completion date changed from 1 Nov 2026 to 1 Nov 2027.
19 Dec 2023 According to Kolon TissueGene media release, clinical trial is planned to be conducted in up to 6 hospitals in the United States in 24 patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight